Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.

Bio-Techne (TECH) is back in focus after institutional investors such as Jefferies Financial Group and Madison Investments increased their exposure, alongside earnings that topped expectations and ...

Techne Corporation—whose longtime CEO resigned in November and protested the search process for his successor—said Monday that it has appointed a new chief executive. Techne, a Minneapolis-based maker ...

Shares of Bio-Techne Corp. TECH rallied 1.82% to $54.87 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.83% to 6,795.99 and ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for “Madison Mid Cap Fund”. A copy of the letter can be downloaded here. The Russell Midcap Index ended an ...

The collaboration between Leica Biosystems and Bio-Techne expands access to advanced RNA ISH technology for clinical laboratories across the United States ...

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...

Techne Corporation announced Monday that it is changing its name to “Bio-Techne” as part of a “new strategic direction.” The Minneapolis-based biotech company said that, in conjunction with its ...